Aurobindo Pharma receives tentative FDA approval for Lamivudine

By Jennifer Chiou

New York, Nov. 7 - Aurobindo Pharma Ltd. said the U.S. Food and Drug Administration granted tentative approval for its Lamivudine oral solution.

Lamivudine is an antiviral drug called a nucleoside reverse transcriptase inhibitor for infections due to hepatitis B and in combination with other medications for human immunodeficiency virus.

Aurobindo noted Lamivudine is the first generic version to be approved of Epivir oral solution produced by GlaxoSmithKline.

Including Lamivudine, the company has eight product approvals under president George Bush's Emergency Plan for AIDS Relief program.

The Hyderabad, Andhra Pradesh, India, company makes generic pharmaceuticals and pharmaceutical ingredients.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.